Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study

Allergy. 2024 Sep 17. doi: 10.1111/all.16322. Online ahead of print.

Authors

Manali Mukherjee^{1

2}, Jaime Bernaola^{1

2}, Santi Nolasco^{2

3}, Melanie Kjarsgaard², Yinglan Xie¹, Katherine Radford², Bashayr Alotaibi¹, Carmen Venegas Garrido^{1

2}, Parameswaran Nair^{1

2}

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
² Research Institute of St. Joe's. St Joseph's Healthcare, Hamilton, Ontario, Canada.
³ Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

PMID: 39286951
DOI: 10.1111/all.16322

No abstract available

Keywords: anti‐IL‐5 biologic; cytokines; eosinophils; reslizumab; severe asthma; sputum.

Publication types

Letter

Grants and funding

Teva Canada Innovation